Registry for esophageal cancer that has spread to a few spots
Part of Cancer, Digestive system clinical trials.
This study tracks patients with stage IV esophageal or gastroesophageal junction cancer that has spread to only a limited number of places (like the liver, lung, or a few lymph nodes). The goal is to understand how well treatments like surgery or radiation work after initial drug therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV cancer of the esophagus or where the esophagus meets the stomach
- Your cancer has spread to 5 or fewer total spots and no more than 2 different organ systems (like liver or lung)
- All spots of cancer can be treated completely with surgery, radiation, or similar methods after initial drug therapy
- You are 18 years or older
- You do not have cancer spread to the lining of the belly area, brain, or fluid around the lungs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
This trial combines a special high-dose radiation (SBRT) with immunotherapy to treat esophageal cancer that has spread to a few spots in the body (up to 5 spots in up to 3 organs). The goal is to see if this approach can better control the cancer.
This trial tests a combination of an immunotherapy drug (bemosubaymab), a targeted therapy (anlotinib), radiation therapy, and chemotherapy for patients with esophageal cancer that has spread to a limited number of spots (no more than 5). The goal is to see if this combination can shrink or control the cancer.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
Hear when a new Gastroesophageal-junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.